Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431273 · ClinicalTrials.gov registry record · Early Phase 1
Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women
A Early Phase 1 study, sponsored by Auritec Pharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT02431273 is a Early Phase 1 study that has completed, run by Auritec Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT02431273, a Early Phase 1 study, has completed, sponsored by Auritec Pharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate the hypothesis that intravaginal rings (IVRs) can safely and in a sustained fashion, deliver the antiretroviral (ARV) drugs - tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and maraviroc (MVC), in healthy women when used in the following drug combinations: 1) TDF ("Single" IVR); 2) TDF-FTC ("Dual" IVR) and; 3) TDF-FTC-MVC ("Triple" IVR). TDF = tenofovir disoproxil fumarate; FTC = emtrcitabine; MVC = maraviroc
Interventions
- DRUG TDF IVR
- DRUG TDF-FTC IVR
- DRUG TDF-FTC-MVC IVR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431273
The ClinicalTrials.gov registry entry for NCT02431273 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Auritec Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TDF IVR is the first listed.
NCT02431273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431273 about?
NCT02431273 is a clinical study titled "Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women". This study will evaluate the hypothesis that intravaginal rings (IVRs) can safely and in a sustained fashion, deliver the antiretroviral (ARV) drugs - tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and maraviroc (MVC), in healthy women when used in the following drug combinations: 1) TDF ...
What is the current status of trial NCT02431273?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2015-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02431273?
The interventions under investigation include: TDF IVR (DRUG), TDF-FTC IVR (DRUG), TDF-FTC-MVC IVR (DRUG).
Who is sponsoring clinical trial NCT02431273?
This trial is sponsored by Auritec Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.